B-Cell Non-Hodgkin’s Lymphoma (NHL) – Opportunity Analysis and Forecasts to 2027
All the vital news, analysis, and commentary curated by our industry experts.
Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of proliferative malignancies that arise in the B cells, T cells, or natural killer (NK) cells within the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen. B-cell lymphomas comprise approximately 85% of all NHL cases diagnosed in the US, and are a diverse group of blood cancers that arise in the B-cells. This report focuses on the four NHL subtypes that represent the greatest commercial opportunities for drug developers during the forecast period: Diffuse large B-cell lymphoma (DLBCL), Follicular lymphoma (FL), Marginal zone lymphoma (MZL) and Mantle cell lymphoma (MCL).
The introduction of Roche’s Rituxan/MabThera (rituximab) in the late 1990s revolutionized NHL therapy, and the market is now dominated by Rituxan. However, NHL patients frequently become refractory to Rituxan therapy or relapse after responding to the first-line treatment, which has spurred R&D efforts to address therapeutic options for relapsed/refractory (R/R) patients after first-line Rituxan-based therapy.
GlobalData valued the B-cell NHL (FL,MZL,DLBCL and MCL) market at $5.7B in 2017 in the 7MM (US, France, Germany, Italy, Spain, UK and Japan) and expects the market to increase to $9.2B in 2027 at a Compound Annual Growth Rate (CAGR) of 4.9%. Growth will be driven by the rise of chimeric antigen receptor (CAR)-T cell therapies, the launch of six pipeline agents, and the label expansion of currently marketed therapies across the B-cell NHL subtypes. However, growth will be tempered by the biosimilar and generic erosions of Rituxan, Treanda, Gazyva, Revlimid, Imbruvica, Zydelig, Velcade, and Torisel.
Key Questions Answered
Which pipeline agents are the most promising and expected to launch in the 7MM? What are the forecasted sales of these agents and what will be their impact in the B-cell NHL market?
What are the main unmet needs in B-cell NHL , which pipeline drugs will fulfill these needs, and to what extent?
What are the current research and development (R&D) strategies being explored and how can developers incorporate these methods into their business strategy?
Key Opinions Leaders (KOLs) insights across the 7MM, relating to the current treatment options and opinions on the late and early stage pipeline agents.
Overview of B-cell NHL (FL, MZL, DLBCL and MCL), including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
Annualized CLL therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven geographic regions, forecast from 2017 to 2027. Forecast model includes previously diagnosed and newly diagnosed patients.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the B-cell NHL therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for B-cell NHL . The most promising candidates in late-stage development are profiled.
Analysis of the current and future market competition in the global B-cell NHL market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Growth will be driven by the rise of CAR-T cell therapies, the launch of six pipeline agents, and the label expansion of currently marketed therapies across the B-cell NHL subtypes.
Lisocabtagene maraleucel, ublituximab + umbralisib and Polivy are the three pipeline/upcoming therapies expected to generate the highest sales for B-cell NHL from 2017-2027.
Several unmet needs still remain in B-cell NHL, and while it is unlikely that they will be fully met within the forecast period, progress will be made on many of those needs.
The growth of the B-cell NHL market will be tempered by the patent expiry of leading brands, including Rituxan, Treanda, Gazyva, Revlimid, Imbruvica, Zydelig, and Velcade, and subsequent biosimilar/generic erosion
Lack of, or delayed, clinical development in Japan, will result in marketing approval of only a subset of the pipeline candidates in that region during the forecast period
Reasons to Buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global B-cell NHL market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global B-cell NHL market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Acerta Pharma BV
Cabaret Biotech Ltd
Denovo Biopharma LLC
Eagle Pharmaceuticals Inc.
Johnson & Johnson
Napp Pharmaceuticals Ltd
TG Therapeutics Inc.
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 B-Cell NHL: Executive Summary
2.1 The B-Cell NHL Market Is Expected to Grow to $9.2B in 2027
2.2 Combinations with Rituxan and Label Expansions Across B-Cell NHL Will Continue to Be the Prominent Strategies Utilized by Developers
2.3 Moderate Level of Overall Unmet Need, but Opportunities Remain in Specific Settings
2.4 Large Pipeline Composed of Therapies with Relatively High Potential
2.5 What Do Physicians Think?
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for B-Cell NHL (2017–2027)
5.5.1 Diagnosed Incident Cases of B-Cell NHL
5.5.2 Age-Specific Diagnosed Incident Cases of B-Cell NHL
5.5.3 Sex-Specific Diagnosed Incident Cases of B-Cell NHL
5.5.4 Diagnosed Incident Cases of DLBCL, FL, MZL, and MCL
5.5.5 Diagnosed Incident Cases of DLBCL by Cancer Staging
5.5.6 Diagnosed Incident Cases of FL by Cancer Staging
5.5.7 Diagnosed Incident Cases of MZL by Cancer Staging
5.5.8 Diagnosed Incident Cases of MCL by Cancer Staging
5.5.9 Diagnosed Incident Cases of FL by Grade
5.5.10 Diagnosed Prevalent Cases of B-Cell NHL
5.5.11 Diagnosed Prevalent Cases of DLBCL, FL, MZL, and MCL
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis
6 Current Treatment Options
6.1.1 Agents Used Across the Four Subtypes and Across Lines of Therapy
6.1.2 Rituxan Hycela, Rituximab Biosimilars, and Gazyva
6.1.3 Small Molecule Inhibitors in MCL, FL, and MZL
6.1.4 CAR-T Therapy in DLBCL
7 Unmet Needs and Opportunity Assessment
7.2 Predictive and Prognostic Molecular Biomarkers
7.2.1 GCB and Non-GCB Histology in DLBCL
7.2.2 Patients Who Are Not Cured with 1L R-CHOP in DLBCL
7.2.3 The POD24 Group in FL
7.2.4 DGM1-Positive Patients in DLBCL
7.3 Improvement of Cure Rate and Better Therapies for DLBCL Patients Who Are Not Cured by 1L R-CHOP
7.4 Further Options in FL for Various Patient Subsets
7.5 Patients Refractory to/Relapsed after Treatment with Imbruvica in MCL
7.6 Clinical Research in MZL
8 R&D Strategies
8.1.1 Label Expansions to Additional NHL Subtypes and Lines of Therapy
8.1.2 Novel Mechanisms of Action
8.1.3 Exploration of Novel Combinations With and Without Rituxan
8.2 Clinical Trials Design
8.2.1 Ongoing Late-Stage Trials of Marketed and Pipeline Drugs
8.2.2 PFS is the Most Common Clinical Trial Endpoint
8.2.3 Comparator Arms
9 Pipeline Assessment
10 Pipeline Valuation Analysis
10.1 Clinical Benchmark of Key Pipeline and Marketed Drugs
10.2 Commercial Benchmark of Key Pipeline Drugs
10.3 Competitive Assessment
10.4 Top-Line 10-Year Forecast
11.3.1 Forecasting Methodology
11.3.2 Diagnosed Patients
11.3.3 Percent Drug-Treated Patients
11.3.4 Drugs Included in Each Therapeutic Class
11.3.5 Launch and Patent Expiry Dates
11.3.6 General Pricing Assumptions
11.3.7 Individual Drug Assumptions
11.3.8 Generic Erosion
11.3.9 Pricing of Pipeline Agents
11.4 Primary Research – KOLs Interviewed for This Report
11.5 Primary Research – Prescriber Survey
11.6 About the Authors
11.6.2 Therapy Area Directors
11.6.4 Managing Epidemiologist
11.6.5 Global Director of Therapy Analysis and Epidemiology
11.6.6 Global Head and EVP of Healthcare Operations and Strategy
11.7 About GlobalData
11.8 Contact Us
Frequently asked questions
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Business Intelligence & Marketing Manager, SAL Heavy Lift
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
Market Analyst & Management, Liebherr-Werk
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Head of Key Accounts, Saab AB
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Marketing Intelligence Manager, Portugal Foods
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Head of Customer Insight and Research, Standard Chartered
Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.
I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.
I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.
Head of Consumer Sensory Insights, Givaudan
“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.
Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”
Senior Account Manager, TSYS
GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.
I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.
One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.